P059 Cutaneous sarcomas: a 5-year review of treatment outcomes and literature

Jenny Chung,Chrystalla Macedo,Rishika Sinha

DOI: https://doi.org/10.1093/bjd/ljae090.086

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Cutaneous sarcomas comprise 5% of skin cancers yet carry great morbidity and mortality. They include atypical fibroxanthoma (AFX), pleomorphic dermal sarcoma (PDS), leiomyosarcoma (LMS), dermatofibrosarcoma protuberans (DFSP) and angiosarcoma (AS) (Stoneham S, Hunter A, Raahimi M et al. Cutaneous sarcoma: a review and practical approach to management. Clin Exp Dermatol 2023; 48: 866–72). Standardized agreed national guidelines for the management of these rare tumours are lacking, and we rely on guidance from sarcoma specialists (Dangoor A, Seddon B, Gerrand C et al. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 2016; 6: 20). However, these tumours are lower grade, and do not carry the same local and metastatic recurrence risk as noncutaneous sarcomas. The aim of this study at a tertiary UK centre was to review the treatment and follow-up outcomes of patients with sarcoma managed locally. All patients with biopsy-proven cutaneous sarcomas discussed at our skin cancer multidisciplinary team (MDT) from March 2020 to January 2024 were retrospectively reviewed. Patient demographics, and histology were gathered along with the treatments offered, recurrence and follow-up outcome. All patients were restaged using the American Joint Committee on Cancer soft tissue sarcoma criteria. In total 40 patients met the criteria; their mean age at diagnosis was 70 years (range 24–91) and 25% were immunosuppressed. The cohort was followed up for an average of 11.3 weeks (range 1–36). The diagnoses included PDS (35%), AFX (20%), LMS (20%), DFSP (15%) and AS (5%); all but one had T1 or T2 disease. Overall, 97% of patients received surgery first line, with a clearance rate of 85% (29 of 34). Two patients had recurrence: one with PDS, requiring further surgery, and one with AS, who was managed at a sarcoma unit. There were no metastases reported or deaths due to disease. Most patients (80%) remain in clinical remission. Appropriate imaging and follow-up recommendations were made in most cases, according to their diagnosis. In summary, many of the patients with cutaneous sarcoma in the study had superficial disease. Despite our conservative surgical margins offered and a short duration of follow-up, we observed a 5% recurrence rate with no metastases. This study highlights the importance of an MDT approach to cutaneous sarcomas, which helps draw expertise from different specialties. Our lower recurrence rate and metastases compared with literature suggests that patients with cutaneous sarcoma could be safely managed in local skin cancer MDTs. We propose national guidance to help similar skin cancer MDTs and clinicians to standardize and reduce variation in care, as well as to provide an evidence base on which to recommend monitoring of this rare group of tumours.

dermatology